This article is more than 5 years old. Information may no longer be current.

VIDEO: Progress in antibodies, promise of CAR T cells shifting lymphoma treatment landscape

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Joshua Brody, MD, director of the Lymphoma Immunotherapy Program, Icahn School of Medicine at Mount Sinai Hospital in New York, launches a multi-part video interview talking about the success of passive immunotherapy within the subspecialty.

Brody puts the prevalence of lymphoma in context with other cancers, emphasizes the potential of immune strategies in lymphoid malignancies — many common forms yet incurable — and details the mechanisms of passive options.

Brody highlights approved antibodies rituximab (Rituxan; Genentech, Biogen Idec), ofatumumab (Arzerra, Novartis) and obinutuzumab (Gazyva, Roche), then looks to the future with chimeric antigen receptor T cells, particularly in diffuse large cell and other aggressive lymphomas.

“Passive immunotherapies have already shown great promise, and we have very clear directions for how to improve upon both antibody therapy and CAR T-cell therapy in the next 1 to 3 years,” he says.